KeyBanc analyst Matthew Gillmor lowered the firm’s price target on Acadia Healthcare (ACHC) to $25 from $30 and keeps an Overweight rating on the shares. The firm notes the company reduced its 2025 EBITDA guidance another 7% to reflect a further PLGL cost increase following its annual third-party actuary review. While this event shouldn’t be thesis altering, it will further erode already-extremely-low investor confidence, KeyBanc adds.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- BofA downgrades Acadia Healthcare to Underperform after another guidance cut
- Acadia Healthcare downgraded to Underperform from Neutral at BofA
- Acadia Healthcare downgraded to Market Perform from Outperform at Leerink
- Acadia Healthcare price target lowered to $20 from $33 at Deutsche Bank
- Acadia Healthcare Stock (ACHC) Plunges on Guidance Cut